Advertisement
Screener

SCIENTURE HOLDINGS, INC. (SCNX) Operating Expenses

2.8 / 5 stars · 68/120 Roast Me

SCIENTURE HOLDINGS, INC. Operating Expenses

SCIENTURE HOLDINGS, INC. (SCNX) reported Operating Expenses of $3.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:OperatingExpenses · last filed 2026-08-13

  • SCIENTURE HOLDINGS, INC. operating expenses for the quarter ending 2026-06-30 was $3.04M, a 41.15% decline year-over-year.
  • SCIENTURE HOLDINGS, INC. operating expenses for the quarter ending 2026-03-31 was $3.56M, a 0.24% decline year-over-year.
  • SCIENTURE HOLDINGS, INC. operating expenses for the quarter ending 2025-12-31 was $29.26M, a 593.71% increase year-over-year.
  • SCIENTURE HOLDINGS, INC. operating expenses for the quarter ending 2025-09-30 was $4.94M, a 40.96% increase year-over-year.
  • SCIENTURE HOLDINGS, INC. operating expenses for fiscal 2025 was $42.92M, a 191.85% increase from fiscal 2024.
  • SCIENTURE HOLDINGS, INC. operating expenses for fiscal 2024 was $14.71M, a 230.83% increase from fiscal 2023.
  • SCIENTURE HOLDINGS, INC. operating expenses for fiscal 2023 was $4.45M, a 47.30% decline from fiscal 2022.
  • SCIENTURE HOLDINGS, INC. operating expenses for fiscal 2022 was $8.44M, a 15.97% decline from fiscal 2021.
Period endOperating Expenses 3 monthOperating Expenses 3 month as first filedOperating Expenses 6 monthOperating Expenses 6 month as first filedOperating Expenses 9 monthOperating Expenses 9 month as first filedOperating Expenses 12 monthOperating Expenses 12 month as first filed
2026-06-30$3.04M
10-Q · filed 2026-08-13
$6.60M
10-Q · filed 2026-08-13
$35.86M
derived: sum of 3 quarters · filed 2026-08-13
$40.79M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$3.56M
10-Q · filed 2026-05-15
$32.82M
derived: sum of 2 quarters · filed 2026-05-15
$37.76M
derived: sum of 3 quarters · filed 2026-05-15
$42.91M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$29.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$34.19M
derived: sum of 2 quarters · filed 2026-03-30
$39.35M
derived: sum of 3 quarters · filed 2026-08-13
$42.92M
10-K · filed 2026-03-30
2025-09-30$4.94M
10-Q · filed 2025-11-12
$10.09M
derived: sum of 2 quarters · filed 2026-08-13
$13.67M
10-Q · filed 2025-11-12
$17.88M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$5.16M
10-Q · filed 2026-08-13
$8.73M
10-Q · filed 2026-08-13
$12.95M
derived: sum of 3 quarters · filed 2026-08-13
$16.45M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$3.57M
10-Q · filed 2026-05-15
$7.79M
derived: sum of 2 quarters · filed 2026-05-15
$11.29M
derived: sum of 3 quarters · filed 2026-05-15
$12.79M
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31$4.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$7.72M
derived: sum of 2 quarters · filed 2026-03-30
$9.21M
derived: sum of 3 quarters · filed 2026-03-30
$14.71M
10-K · filed 2026-03-30
2024-09-30$3.50M
10-Q · filed 2025-11-12
$5.00M
derived: sum of 2 quarters · filed 2025-11-12
$10.49M
10-Q · filed 2025-11-12
$12.63M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$1.49M
10-Q · filed 2025-08-12
$6.99M
10-Q · filed 2025-08-12
$9.13M
derived: sum of 3 quarters · filed 2025-08-12
$9.93M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31$5.49M
10-Q · filed 2025-05-12
$5.50M
10-Q · filed 2024-06-26
$7.63M
derived: sum of 2 quarters · filed 2025-05-12
$8.43M
derived: sum of 3 quarters · filed 2025-05-12
$9.10M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31$2.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26
$2.94M
derived: sum of 2 quarters · filed 2025-03-26
$3.61M
derived: sum of 3 quarters · filed 2025-03-26
$4.45M
10-K · filed 2025-03-26
$9.86M
10-K · filed 2024-04-22
2023-09-30$801.27K
10-Q · filed 2024-11-06
$2.55M
10-Q · filed 2024-01-16
$1.47M
derived: sum of 2 quarters · filed 2024-11-06
$2.31M
10-Q · filed 2024-11-06
$5.92M
10-Q · filed 2024-01-16
$4.93M
derived: sum of 4 quarters · filed 2024-11-06
2023-06-30$666.92K
10-Q · filed 2024-08-09
$1.99M
10-Q · filed 2023-08-18
$1.50M
10-Q · filed 2024-08-09
$3.89M
10-Q · filed 2023-08-18
$4.13M
derived: sum of 3 quarters · filed 2024-08-09
$5.72M
derived: sum of 4 quarters · filed 2024-08-09
2023-03-31$879.31K
10-Q · filed 2024-06-26
$1.90M
10-Q · filed 2023-05-15
$3.46M
derived: sum of 2 quarters · filed 2024-06-26
$5.05M
derived: sum of 3 quarters · filed 2024-06-26
$7.32M
derived: sum of 4 quarters · filed 2024-06-26
2022-12-31$2.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-22
$4.17M
derived: sum of 2 quarters · filed 2024-04-22
$6.44M
derived: sum of 3 quarters · filed 2024-04-22
$8.44M
10-K · filed 2024-04-22
$9.88M
10-K · filed 2023-03-27
2022-09-30$1.59M
10-Q · filed 2024-01-16
$1.81M
10-Q · filed 2022-11-07
$3.87M
derived: sum of 2 quarters · filed 2024-01-16
$5.86M
10-Q · filed 2024-01-16
$6.39M
10-Q · filed 2022-11-07
$8.19M
derived: sum of 4 quarters · filed 2024-01-16
2022-06-30$2.27M
10-Q · filed 2023-08-18
$4.58M
10-Q · filed 2023-08-18
$6.60M
derived: sum of 3 quarters · filed 2023-08-18
$9.18M
derived: sum of 4 quarters · filed 2023-08-18
2022-03-31$2.30M
10-Q · filed 2023-05-15
$4.33M
derived: sum of 2 quarters · filed 2023-05-15
$6.90M
derived: sum of 3 quarters · filed 2023-05-15
$10.31M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31$2.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27
$4.60M
derived: sum of 2 quarters · filed 2023-03-27
$8.01M
derived: sum of 3 quarters · filed 2023-03-27
$10.04M
10-K · filed 2023-03-27
2021-09-30$2.58M
10-Q · filed 2022-11-07
$5.99M
derived: sum of 2 quarters · filed 2022-11-07
$8.02M
10-Q · filed 2022-11-07
2021-06-30$3.41M
10-Q · filed 2022-07-25
$5.44M
10-Q · filed 2022-07-25
2021-03-31$2.03M
10-Q · filed 2022-05-09
2020-12-31$8.21M
10-K · filed 2022-03-28
2019-12-31$4.75M
10-K · filed 2021-03-29
2018-12-31$3.47M
10-K · filed 2020-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
KIORA PHARMACEUTICALS INC (KPRX)United States$0.012B
Phio Pharmaceuticals Corp. (PHIO)United States$0.012B-0.92
ADIAL PHARMACEUTICALS, INC. (ADIL)United States$0.012B
Dare Bioscience, Inc. (DARE)United States$0.011B
BIOVIE INC. (BIVI)United States$0.012B
Aspire Biopharma Holdings, Inc. (ASBP)United States$0.012B-0.60
Tempest Therapeutics, Inc. (TPST)United States$0.013B
Moleculin Biotech, Inc. (MBRX)United States$0.011B
MetaVia Inc. (MTVA)United States$0.011B-0.65
KALA BIO, Inc. (KALA)United States$0.011B-3.33